[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591761":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":29,"locations":36,"responsibleParty":170,"collaborators":28,"id":172,"slug":28,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":28,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":28,"studyType":184,"phases":185,"briefSummary":187,"conditions":188,"keywords":28,"overallStatus":39,"whyStopped":28,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rilzabrutinib dose 1","EXPERIMENTAL","Rilzabrutinib",[13],"Drug: Rilzabrutinib dose 1",{"label":15,"type":10,"description":11,"interventionNames":16},"Rilzabrutinib dose 2",[17],"Drug: Rilzabrutinib dose 2",[19,25],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Pharmaceutical form:Tablet-Route of administration:Oral",[9],[24],"SAR444671",{"type":20,"name":15,"description":21,"armGroupLabels":26,"otherNames":27},[15],[24],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Trial Transparency email recommended (Toll free for US & Canada)","CONTACT","800-633-1610","option 6","Contact-US@sanofi.com",[37,50,60,70,80,89,100,109,118,129,139,149,160],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":28},"Investigational Site Number : 1240003","RECRUITING","Calgary","Alberta","T2N 4L7","Canada",{"type":45,"coordinates":46},"Point",[47,48],-114.08529,51.05011,{"lat":48,"lon":47},{"facility":51,"status":39,"city":52,"state":53,"zip":54,"country":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":28},"Investigational Site Number : 1240002","Surrey","British Columbia","V3T 4G8",{"type":45,"coordinates":56},[57,58],-122.82509,49.10635,{"lat":58,"lon":57},{"facility":61,"status":39,"city":62,"state":63,"zip":64,"country":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":28},"Investigational Site Number : 1240001","Sherbrooke","Quebec","J1H 5N4",{"type":45,"coordinates":66},[67,68],-71.89908,45.40008,{"lat":68,"lon":67},{"facility":71,"status":39,"city":72,"state":28,"zip":73,"country":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":28},"Investigational Site Number : 2760002","Essen","45147","Germany",{"type":45,"coordinates":76},[77,78],7.01228,51.45657,{"lat":78,"lon":77},{"facility":81,"status":39,"city":82,"state":28,"zip":83,"country":74,"cosmosGeoPoint":84,"geoPoint":88,"contacts":28},"Investigational Site Number : 2760001","Frankfurt","60590",{"type":45,"coordinates":85},[86,87],10.53333,49.68333,{"lat":87,"lon":86},{"facility":90,"status":39,"city":91,"state":92,"zip":93,"country":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":28},"Investigational Site Number : 3800001","Milan","Milano","20122","Italy",{"type":45,"coordinates":96},[97,98],9.18951,45.46427,{"lat":98,"lon":97},{"facility":101,"status":39,"city":102,"state":28,"zip":103,"country":94,"cosmosGeoPoint":104,"geoPoint":108,"contacts":28},"Investigational Site Number : 3800003","Palermo","90127",{"type":45,"coordinates":105},[106,107],13.3636,38.1166,{"lat":107,"lon":106},{"facility":110,"status":39,"city":111,"state":28,"zip":112,"country":94,"cosmosGeoPoint":113,"geoPoint":117,"contacts":28},"Investigational Site Number : 3800002","Pisa","56126",{"type":45,"coordinates":114},[115,116],10.4036,43.70853,{"lat":116,"lon":115},{"facility":119,"status":39,"city":120,"state":121,"zip":122,"country":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":28},"Investigational Site Number : 7240002","Barcelona","Catalunya [Cataluña]","08036","Spain",{"type":45,"coordinates":125},[126,127],2.15899,41.38879,{"lat":127,"lon":126},{"facility":130,"status":39,"city":131,"state":132,"zip":133,"country":123,"cosmosGeoPoint":134,"geoPoint":138,"contacts":28},"Investigational Site Number : 7240001","Pamplona","Navarre","31008",{"type":45,"coordinates":135},[136,137],-1.64323,42.81687,{"lat":137,"lon":136},{"facility":140,"status":39,"city":141,"state":142,"zip":143,"country":123,"cosmosGeoPoint":144,"geoPoint":148,"contacts":28},"Investigational Site Number : 7240004","Seville","Sevilla","41009",{"type":45,"coordinates":145},[146,147],-5.97317,37.38283,{"lat":147,"lon":146},{"facility":150,"status":39,"city":151,"state":152,"zip":153,"country":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":28},"Investigational Site Number : 8260003","Milton Keynes","Buckinghamshire","MK6 5LD","United Kingdom",{"type":45,"coordinates":156},[157,158],-0.75583,52.04172,{"lat":158,"lon":157},{"facility":161,"status":39,"city":162,"state":163,"zip":164,"country":154,"cosmosGeoPoint":165,"geoPoint":169,"contacts":28},"Investigational Site Number : 8260001","Newcastle upon Tyne","England","NE2 4HH",{"type":45,"coordinates":166},[167,168],-1.61396,54.97328,{"lat":168,"lon":167},{"type":171,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100591761",false,"NCT06984627","A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening.\n* A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (CAS) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and\u002For intermittent or constant diplopia.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by Graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis).\n* History of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician.\n* Enlarged thyroid goiter causing upper airway obstruction and\u002For requiring surgical intervention during the study period.\n* For participant with Graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery\u002Firradiation during the course of the study.\n* Sight threatening Graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months.\n* Corneal decompensation unresponsive to medical management.\n* Onset of Graves' orbitopathy symptoms \\>9 months prior to baseline.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":182,"type":183},30,"ESTIMATED","INTERVENTIONAL",[186],"PHASE2","This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.\n\nStudy details include:\n\n* Screening period (up to 4 weeks).\n* Treatment period (up to 16 weeks).\n* Follow-up period (4 weeks). The number of visits will be up to 13.",[189],"Graves' Disease","2026-05-21",{"date":192,"type":193},"2026-05-22","ACTUAL",{"date":195,"type":193},"2025-09-02",{"date":197,"type":183},"2026-09-23",{"name":5,"class":6},13]